Viyash Scientific · risk themes across the available quarters.
Bear-case history
API grew only 2.9% YoY in Q3 despite strong 9-month performance. Management attributed this to CDMO contract timing delays pushing into next quarter, but this raises questions about API momentum sustainability.
US human health formulation struggled with post-COVID inventory buildup and Indian cost competition. Management's pivot to complex products and backward integration is underway but only 45% of key products commercialized so far—execution risk remains.
While only 15-16% genericized (vs 85-90% in human health), the pace of genericization depends on market development, regulatory approvals, and innovator strategy. Management expects acceleration but timing remains uncertain.
Analyst specifically asked about North American formulation expansion post-merger. Management responded that supply chain understanding and product basket development requires time, making this a Phase 2 priority—meaning meaningful North American revenue may be 3+ years away.